Dr Ho Choon Hou
Dr Ho Choon Hou was first appointed as a Director of the Company in June 2011 and was last re-elected on 26 April 2019. He was re-designated as an Independent Director on 22 May 2018. Dr Ho was appointed as Acting Chairman of the Board in October 2020.
Dr Ho is a Managing Director at Southern Capital Group Limited, where he is responsible for the origination and execution of investments. He is also an Independent Director of Advanced Holdings Limited, Vividthree Holdings Ltd. and Mclean Berhad.
Dr Ho holds a Bachelor of Medicine and Bachelor of Surgery (Honours) from the University of Sheffield, as well as a Master of Medicine (Surgery) from the National University of Singapore and a Master of Business Administration (Honours) from the University of Chicago (Graduate School of Business).
Ms Tan Poh Lan
Ms Tan Poh Lan was first appointed as Group Chief Operating Officer of the Company on 12 April 2016. She was appointed as Executive Director and Group Chief Executive Officer on 28 February 2019 and was last re-elected on 26 April 2019.
Ms Tan has 30 years of extensive experience in the private and public healthcare sectors. Prior to her current portfolio, she was the Chief Executive Officer in both regional and local hospitals, namely Parkway East Hospital (formerly East Shore Hospital) and Gleneagles Hospital in Singapore, Vinmec International Hospital in Hanoi, Vietnam and Fortis Healthcare Singapore.
Ms Tan holds a Master of Business Administration from National University of Singapore and graduated with Honours in Occupational Therapy from University of Queensland, Australia.
Mr Joseph Wong Wai Leung
Mr Joseph Wong Wai Leung was appointed as an Independent Director of the Company on 23 September 2014 and was last re-elected on 27 October 2017.
Mr Wong has a wealth of experience in the financial services industry. He started his career at Big Four auditing firms, PricewaterhouseCoopers and Deloitte Touche Tohmatsu, Hong Kong ("Deloitte").
At Deloitte, he was engaged in a wide spectrum of business domains, including initial public offerings, taxation, and asset protection plans for high net worth individuals. Subsequently, he worked at Credit Agricole ("Suisse"), Hong Kong, where he advised clients on wealth management.
Mr Wong holds a Bachelor of Commerce from the University of Calgary in Alberta, Canada.
Mr Yeo Hwee Tiong
Mr Yeo Hwee Tiong was appointed as an Independent Director of the Company on 22 May 2018 and was last re-elected on 26 April 2019.
Mr Yeo is currently the Group Chief Executive Officer with the Singapore Women's & Children's Medical Group. He has more than 28 years in the healthcare and project management industry and has been involved in the pre-development and planning, construction, project management, hospital management and restructuring of hospitals in Singapore, Malaysia, Myanmar and Vietnam. Mr Yeo was instrumental in the restructuring and turning around of three hospitals in Singapore and Malaysia. Of these, he listed two in Singapore. Mr Yeo also has experience in Vietnam, taking a greenfield hospital project from inception to completion, and into hospital management. On project management sector, Mr Yeo has been involved at senior level in Singapore, India, Vietnam and New Zealand where he project-managed large office complexes, air terminals, industrial park, microwave tower, medical centres and hospitals.
Prior to his current portfolio, Mr Yeo was the Principal at KPMG, Deal Advisory, Healthcare (Singapore and Asia Pacific). He was responsible in setting up the healthcare division for KPMG Singapore and was also appointed as the Healthcare Lead for Asia Pacific working alongside KPMG Global Healthcare based in UK. Mr Yeo led in many clients' engagements on the healthcare landscape in Myanmar, Vietnam, India, Thailand, Indonesia, the Philippines, China, Sri Lanka, Malaysia and presented many market entry opportunities and advisory services to KPMG's clients. He was also involved in commercial due diligence, market research, M&A, restructuring, greenfield advisory, business improvements and clinical due diligence of medical practices and hospitals in Singapore and in the region.
Mr Yeo has managed public hospital in Singapore and private hospitals in Singapore, Malaysia and Vietnam and as its Group CEO, has clear oversight responsibility in ensuring the proper management of the hospitals under his charge.
Mr Yeo obtained his Bachelor of Science (Building) from Heriot-Watt University, Edinburgh, United Kingdom. He also holds a Master of Science (Project Management) from National University of Singapore.
Mr Zhai Lingyun
Mr Zhai Lingyun was appointed as a Non-Independent Non-Executive Director of the company on 12 December 2019.
Mr Zhai is currently the Chairman of Nanjing Cenbest Group Co., Ltd. He is also the Chairman of Dendreon Pharmaceuticals LLC, an immunotherapy company based in California US and Natali Seculife Holdings Ltd, the largest private healthcare services company in Israel.
Prior to his current portfolio, Mr Zhai was General Manager of Anhui Branch of Ping An Annuity Insurance Company of China, Ltd for 6 years. Subsequently, he joined Anhui Xinhua Distribution (Group) Holding Co., Ltd as Deputy General Manager. During his stint of 6 years overseeing and managing this traditional large-scale state-owned group in culture and media, he reformed the entire management system, revitalized its business and regained its market position.
In his last position in the Group, he served as Vice Chairman and General Manager of Anhui Xinhua Media Co., Ltd., a holding company listed on Shanghai Stock Exchange ("SSE") where the company achieved remarkable gains in market capitalisation under his stewardship.
Mr Zhai holds a Certificate in Economics from Anhui Investment Management Institute. He also obtained his MBA in Financial Management from University of Luton, UK. In addition, he was accredited as Senior Economist by Personnel Department of Anhui Province, China and awarded Certificate of Advanced Management Programme from China Europe International Business School (CEIBS), China.
Mr Chang Chien
Mr Chang Chien was appointed as a Non-Independent Non-Executive Director of the company on 12 December 2019.
Mr Chang Chien is currently the Director of Citichamp (Holdings) Limited, where he manages and oversees the company's investment portfolios, operation, business development and corporate compliance agendas. Citichamp (Holdings) Limited is a large multi-national conglomerate that integrates the capital, talents and know-how to manage investments in Asia. He is also the Director of Outward Shine Limited.
Prior to joining Citichamp (Holdings) Limited, he was a Deputy General Manager and Responsible Officer under Securities and Futures Commission ("SFC") requirements at Shun Heng Securities Limited for 3 years. He was then appointed as the Director of the board, responsible for business operation, risk management and institutional order execution.
He continued to pursue greater heights in his career as a Sales Director in China Yinsheng International Securities Limited, where he was responsible in devising the company's business development strategies and developing long-term business relationship with clients. He was also the SFC-required Responsible Officer of China Yinsheng International Securities Limited, with the primary responsibility of managing the company's compliance with all applicable standards of conduct, including statutory requirements of the Securities and Futures Ordinance and codes issued by the SFC.
Mr Chang Chien holds a Bachelor of Arts (Honours) in Public and Social Administrations from City University of Hong Kong.
Mr Fong Chi Wah
Mr Fong Chi Wah was appointed as a Non-Independent Non-Executive Director of the Company on 18 January 2019 and was last re-elected on 26 April 2019.
Mr Fong is currently the Chief Financial Officer cum Company Secretary of CityChamp Watch & Jewellery Group Limited, a company listed on the Hong Kong Stock Exchange ("HKSE") and serves as Director of its subsidiary Bendura Bank Liechtenstein. He is also the Independent Director of China Youzan Limited, listed on HKSE. Previously, he was Executive Director of the National Fund Limited and Independent Director of Real Nutriceutical Group Limited. Both companies are also listed on HKSE.
Mr Fong has over 25 years of extensive experience in various sectors of the financial industry including direct investment, project and structured finance and capital markets. He has worked for renowned financial corporations such as KPMG, the American International Group ("AIG") in Asia, and the ING Group in Beijing and Hong Kong. In his last position within the ING Group, he served as a Director of the Baring Capital (China) Management Limited that managed ING Beijing Investment Co., Ltd., a company listed on the HKSE.
Mr Fong holds a Bachelor's degree, majoring in Management Sciences (Economics) from the Lancaster University, United Kingdom. He also holds three Master's degrees including a Master of Business Administration from the Warwick University, United Kingdom, a Master's degree in Investment Management from the Hong Kong University of Science and Technology, and a Master's degree in practicing accounting from the Monash University, Australia. He has a Doctorate in Business Administration from the Hong Kong Polytechnic University and is a Juris Doctor from the Chinese University of Hong Kong. He is a CFA charterholder, a member of the Hong Kong Society of Financial Analysts, a fellow of the CPA (Australia), a fellow of the HKICPA, a member of the Institute of Certified Management Accountants, Australia, and a fellow of the Hong Kong Institute of Directors.
Ms Wang Lin
Ms Wang Lin was appointed as a Non-Independent Non-Executive Director of the Company on 13 November 2019.
Ms Wang Lin has more than 10 years of experience in the pharmaceutical industry, specialising in business management. She is currently the Assistant President of Sanpower Group Corporation, where she oversees and manages a wide spectrum of business domains in the area of cord blood bank, cell immunotherapy, hospital management, senior care and health management. Prior to joining Sanpower Group Corporation, she was the Senior Consultant of IMS Health (Singapore) and McKinsey & Co. (Shanghai).
Ms Wang obtained her Bachelor of Bioengineering from East China University of Science and Technology. She also holds a Master of Business Administration from INSEAD and a Master's degree in Finance from the University of Bath.